HomeTrialNCT05579548
🔬NCT05579548RECRUITING

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Study Summary

This is a Phase 4 observational study designed to assess the impact of Palynziq ® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment50 participants
Primary Completion
Lead SponsorBioMarin Pharmaceutical
Data Retrieved2026-04-11 02:55:23.531321+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.